SENSEX
NIFTY
GOLD
USD/INR

Weather

image 13    C

Top News

News

Top / The Economic Times

details

CAPR stock price: Why is Capricor Therapeutics stock surging over 293% today?

CAPR stock: Capricor Therapeutics' stock soared over 293% after its Phase 3 HOPE-3 trial for Duchenne muscular dystrophy showed promising results. The study demonstrated a slowing of skeletal muscle disease progression in nearly 54% of patients and improvement in heart function for 91%. These outcomes support the development of Deramiocel, an experimental cell therapy.

3 Dec 2025 9:23 pm